In a landmark development for diagnostic imaging, Koning Health has officially received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its proprietary Koning Breast CT (KBCT) System. The approval, formalized under ARTG No. 531059, marks a significant leap forward in breast cancer screening and diagnostic capabilities, promising a paradigm shift in how clinicians evaluate breast tissue. By transitioning from traditional, compression-based mammography to advanced, non-compressive cone-beam computed tomography (CBCT), Koning Health is positioning itself at the forefront of patient-centric medical technology.
Main Facts: A New Era of Non-Compressive Imaging
The Koning Breast CT System, specifically the CBCT 1000, represents a departure from the standard of care that has dominated breast imaging for decades. While traditional mammography requires the breast to be flattened between two plates to reduce tissue thickness and dose, the KBCT system employs cone-beam technology to capture high-resolution, volumetric 3D images while the patient lies in a prone position.
The core benefit of this technology is the complete elimination of breast compression. By removing the physical discomfort associated with conventional mammograms, Koning Health aims to improve patient compliance and reduce the "scan anxiety" that often deters individuals from routine screenings. Furthermore, the 3D nature of the images allows for a more comprehensive assessment of tissue, effectively mitigating the common issue of tissue overlap that can obscure anomalies in 2D mammography.
The TGA’s decision to include the system in the Australian Register of Therapeutic Goods (ARTG) grants Koning Health the legal authorization to market and distribute its devices across the Australian healthcare landscape. This move is not merely a bureaucratic success; it is a strategic expansion that targets a sophisticated medical market with a high demand for innovative diagnostic tools.
Chronology: The Path to Australian Adoption
The journey toward TGA approval involved a rigorous validation process, ensuring that the Koning Breast CT system met the stringent safety and efficacy standards required by Australian law.
Initial Development and Validation: Over the past several years, Koning Health focused on refining the CBCT 1000, gathering clinical evidence that demonstrated the system’s ability to detect lesions with high sensitivity and specificity.
Regulatory Engagement: The company engaged in ongoing dialogue with the TGA to demonstrate compliance with international medical device standards, providing detailed technical documentation, risk management assessments, and clinical trial data.
The Brisbane Radiology Partnership: A pivotal moment in the chronology occurred when Brisbane Radiology, a leading diagnostic imaging provider in Australia, identified the potential of the KBCT system. Their early commitment to becoming the first Australian facility to install the technology provided a tangible use-case that bolstered the regulatory application.
Formal Approval (September 2026): The culmination of these efforts resulted in the official listing on the ARTG in September 2026, opening the door for commercial installation and clinical adoption.
Supporting Data: Why 3D Volumetric Imaging Matters
The shift toward 3D imaging is supported by growing clinical evidence that volumetric assessment offers superior diagnostic accuracy compared to traditional projection radiography.
The Problem with 2D Mammography
Traditional mammography is limited by its projectional nature. When a 3D structure is flattened onto a 2D image, healthy tissue can mask underlying tumors, or conversely, overlapping healthy tissue can create "shadows" that mimic the appearance of a mass. This phenomenon often leads to higher false-positive rates, necessitating "call-backs" that cause unnecessary stress and increased healthcare costs.
The CBCT Advantage
The Koning Breast CT system functions differently. By rotating an X-ray source around the breast, the system acquires hundreds of individual projections, which are then reconstructed into a high-fidelity 3D volume.
Isotropic Resolution: The system provides the same high resolution in all planes (axial, sagittal, and coronal), allowing radiologists to navigate through the breast tissue slice-by-slice.
Tissue Characterization: The volumetric data allows for a more precise evaluation of tissue density, which is critical for identifying potential abnormalities in dense breast tissue—a demographic that historically presents a challenge for standard mammography.
Patient Comfort: Because the patient is lying prone with the breast suspended in the imaging aperture, the procedure is inherently more comfortable, potentially improving the rate of regular screening attendance.
Official Responses: Leadership Perspectives
The entry into the Australian market has been met with enthusiasm from both the executive leadership at Koning Health and the clinical community.
Koning Health President David Georges expressed the strategic significance of this milestone:
"This is an important milestone for Koning and for our continued global expansion. We are grateful to everyone who worked tirelessly to bring this technology to Australia, and we look forward to supporting providers as they introduce a new approach to dedicated breast imaging for their patients."
Georges emphasized that Australia is not just a secondary market, but a critical hub for innovation. He noted, "Australia represents an important market for breast imaging innovation, and Brisbane Radiology’s early commitment demonstrates the kind of forward-thinking leadership that helps bring new technologies into clinical practice. We believe this is only the beginning of a much broader opportunity across the country."
The partnership with Brisbane Radiology serves as the cornerstone of the company’s Australian strategy. By working with a well-regarded clinical entity, Koning Health ensures that the technology is integrated into a workflow that prioritizes patient care, rigorous clinical standards, and ongoing medical education.
Implications: The Future of Breast Health in Australia
The introduction of the Koning Breast CT into the Australian healthcare system carries several long-term implications for the medical industry and the patient population.
1. Elevating the Standard of Care
The availability of non-compressive 3D imaging sets a new benchmark. As patients become more aware of the options available to them, there is likely to be a shift in demand toward more comfortable and accurate imaging modalities. This could eventually force a broader shift in how breast health is monitored, with clinics increasingly looking to adopt advanced CT-based solutions to remain competitive.
2. Streamlining Clinical Workflows
While the installation of new hardware requires training and infrastructure adjustments, the long-term impact on clinical workflows could be positive. Fewer "call-backs" due to false positives mean that radiologists can spend more time analyzing complex cases rather than reviewing indeterminate 2D images. This efficiency gain is vital as the demand for diagnostic services continues to rise globally.
3. A Catalyst for Further Regulatory Expansion
Koning Health’s success with the TGA serves as a template for further expansion. Having successfully navigated one of the world’s most stringent regulatory environments, the company is better positioned to leverage this approval when entering other international markets. The TGA’s stamp of approval is widely respected, and it often acts as a signaling mechanism for other regulatory bodies in the Asia-Pacific region.
4. Supporting the "Whole-Patient" Approach
The Koning system is more than just an imaging device; it represents a commitment to the patient experience. In an era where "patient-centered care" is a core pillar of health policy, removing the physical trauma associated with breast screening is a significant step toward making healthcare more accessible and less intimidating.
Conclusion: A New Horizon
As Koning Health prepares to support its first Australian installations, the broader medical community is watching closely. The success of the KBCT system in Brisbane will likely provide the real-world data necessary to justify wider adoption across public and private hospitals in Australia.
By combining cutting-edge volumetric imaging with a profound focus on patient comfort, Koning Health is addressing the two most significant hurdles in breast cancer screening: diagnostic accuracy and patient willingness to participate. As the company continues to work with local partners on installation, training, and clinical adoption, the Australian market stands as a primary example of how technological innovation can reshape the future of preventative medicine.
For the millions of people who undergo breast screenings annually, this development is more than a regulatory update—it is a promise of a more comfortable, accurate, and proactive future for breast health.
